Correlation of radiological and histopathological response after neoadjuvant radiotherapy in soft tissue sarcoma

References

• Haas RL, Delaney TF, O'Sullivan B, et al. Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where? Int J Radiat Oncol Biol Phys. 2012;84(3):572–580.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25(13):1753–1759.
   PubMed Web of Science ®Google Scholar
• Messiou C, Bonvalot S, Gronchi A, et al. Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging. Eur J Cancer. 2016;56:37–44.
   PubMed Web of Science ®Google Scholar
• Wardelmann E, Haas RL, Bovee JV, et al. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. Eur J Cancer. 2016;53:84–95.
   PubMed Web of Science ®Google Scholar
• Schaefer IM, Hornick JL, Barysauskas CM, et al. Histologic appearance after preoperative radiation therapy for soft tissue sarcoma: assessment of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group response score. Int J Radiat Oncol Biol Phys. 2017;98(2):375–383.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Collini P, Messina A, et al. High-grade soft-tissue sarcomas: tumor response assessment–pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology. 2009;251(2):447–456.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Verderio P, Messina A, et al. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer. 2012;118(23):5857–5866.
   PubMed Web of Science ®Google Scholar
• Lansu J, Bovee J, Braam P, et al. Dose reduction of preoperative radiotherapy in myxoid liposarcoma: a nonrandomized controlled trial. JAMA Oncol. 2021;7(1):e205865.
   PubMed Web of Science ®Google Scholar
• Allignet B, Meurgey A, Bouhamama A, et al. Impact of histological subtype on radiological and pathological response after neoadjuvant radiotherapy in soft tissue sarcoma. Eur J Surg Oncol. 2021;47(12):2995–3003.
   PubMed Web of Science ®Google Scholar
• Bonvalot S, Wunder J, Gronchi A, et al. Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: results of a retrospective multicenter study. Eur J Surg Oncol. 2021;47(8):2166–2172.
   PubMed Web of Science ®Google Scholar
• Crombe A, Cousin S, Spalato-Ceruso M, et al. Implementing a machine learning strategy to predict pathologic response in patients with soft tissue sarcomas treated with neoadjuvant chemotherapy. JCO Clin Cancer Inform. 2021;5:958–972.
   PubMed Web of Science ®Google Scholar
• Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19(13):3203–3209.
   PubMed Web of Science ®Google Scholar
• Seldon C, Shrivastava G, Fernandez M, et al. Pathologic response rates after neoadjuvant therapy for sarcoma: a single institution study. Cancers. 2021;13(5):1074.
   PubMed Web of Science ®Google Scholar
• Shah D, Borys D, Martinez SR, et al. Complete pathologic response to neoadjuvant radiotherapy is predictive of oncological outcome in patients with soft tissue sarcoma. Anticancer Res. 2012;32(9):3911–3915.
   PubMed Web of Science ®Google Scholar
• Canter RJ, Martinez SR, Tamurian RM, et al. Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma. Ann Surg Oncol. 2010;17(10):2578–2584.
   PubMed Web of Science ®Google Scholar
• Mullen JT, Hornicek FJ, Harmon DC, et al. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. Cancer. 2014;120(23):3676–3682.
   PubMed Web of Science ®Google Scholar
• Lucas DR, Kshirsagar MP, Biermann JS, et al. Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation. Oncologist. 2008;13(4):451–458.
   PubMed Web of Science ®Google Scholar
• Gannon NP, Stemm MH, King DM, et al. Pathologic necrosis following neoadjuvant radiotherapy or chemoradiotherapy is prognostic of poor survival in soft tissue sarcoma. J Cancer Res Clin Oncol. 2019 May;145(5):1321–1330.
   PubMed Web of Science ®Google Scholar
• Picci P, Bohling T, Bacci G, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. J Clin Oncol. 1997;15(4):1553–1559.
   PubMed Web of Science ®Google Scholar
• Vasquez L, Tarrillo F, Oscanoa M, et al. Analysis of prognostic factors in High-Grade osteosarcoma of the extremities in children: a 15-year single-institution experience. Front Oncol. 2016;6:22.
   PubMed Web of Science ®Google Scholar
• Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106(5):1154–1161.
   PubMed Web of Science ®Google Scholar
• Salah S, Lewin J, Amir E, et al. Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: a systematic review and meta-analysis. Cancer Treat Rev. 2018;69:1–10.
   PubMed Web of Science ®Google Scholar
• Cates JMM. Histologic response to neoadjuvant therapy is not predictive of favorable outcomes in high-grade pleomorphic soft tissue sarcoma. Am J Surg Pathol. 2019;43(4):564–572.
   PubMed Web of Science ®Google Scholar
• Roberge D, Skamene T, Nahal A, et al. Radiological and pathological response following pre-operative radiotherapy for soft-tissue sarcoma. Radiother Oncol. 2010;97(3):404–407.
   PubMed Web of Science ®Google Scholar
• Bonvalot S, Rutkowski PL, Thariat J, et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. Lancet Oncol. 2019;20(8):1148–1159.
   PubMed Web of Science ®Google Scholar
• Le Grange F, Cassoni AM, Seddon BM. Tumour volume changes following pre-operative radiotherapy in borderline resectable limb and trunk soft tissue sarcoma. Eur J Surg Oncol. 2014;40(4):394–401.
   PubMed Web of Science ®Google Scholar
• Betgen A, Haas RL, Sonke JJ. Volume changes in soft tissue sarcomas during preoperative radiotherapy of extremities evaluated using cone-beam CT. J Radiat Oncol. 2013;2(1):55–62.
   PubMedGoogle Scholar
• de Vreeze RS, de Jong D, Haas RL, et al. Effectiveness of radiotherapy in myxoid sarcomas is associated with a dense vascular pattern. Int J Radiat Oncol Biol Phys. 2008;72(5):1480–1487.
   PubMed Web of Science ®Google Scholar
• Pitson G, Robinson P, Wilke D, et al. Radiation response: an additional unique signature of myxoid liposarcoma. Int J Radiat Oncol Biol Phys. 2004;60(2):522–526.
   PubMed Web of Science ®Google Scholar
• Walker EA, Salesky JS, Fenton ME, et al. Magnetic resonance imaging of malignant soft tissue neoplasms in the adult. Radiol Clin North Am. 2011;49(6):1219–1234, vi.
   PubMed Web of Science ®Google Scholar
• Look Hong NJ, Hornicek FJ, Harmon DC, et al. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur J Cancer. 2013;49(4):875–883.
   PubMed Web of Science ®Google Scholar
• Grunwald V, Litiere S, Young R, et al. Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma – An analysis of the EORTC 62012 study of the EORTC STBSG. Eur J Cancer. 2016;64:44–51.
   PubMed Web of Science ®Google Scholar
• Taieb S, Saada-Bouzid E, Tresch E, et al. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis. Eur J Cancer. 2015;51(2):202–209.
   PubMed Web of Science ®Google Scholar
• Winfield JM, Tunariu N, Rata M, et al. Extracranial soft-tissue tumors: repeatability of apparent diffusion coefficient estimates from diffusion-weighted MR imaging. Radiology. 2017;284(1):88–99.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Perlewitz KS, Hayden JB, et al. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res. 2013;19(24):6902–6911.
   PubMed Web of Science ®Google Scholar
• Crombe A, Le Loarer F, Cornelis F, et al. High-grade soft-tissue sarcoma: optimizing injection improves MRI evaluation of tumor response. Eur Radiol. 2019;29(2):545–555.
   PubMed Web of Science ®Google Scholar
• Costa FM, Martins PH, Canella C, et al. Multiparametric MR imaging of soft tissue tumors and pseudotumors. Magn Reson Imaging Clin N Am. 2018;26(4):543–558.
   PubMed Web of Science ®Google Scholar
• Gennaro N, Reijers S, Bruining A, et al. Imaging response evaluation after neoadjuvant treatment in soft tissue sarcomas: where do we stand? Crit Rev Oncol Hematol. 2021;160:103309.
   PubMed Web of Science ®Google Scholar
• Kasper B, Hohenberger P, Strauss LG, et al. The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas. Hell J Nucl Med. 2010;13(1):40–44.
   PubMed Web of Science ®Google Scholar
• Herrmann K, Benz MR, Czernin J, et al. 18F-FDG-PET/CT imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res. 2012;18(7):2024–2031.
   PubMed Web of Science ®Google Scholar
• Peeken JC, Neumann J, Asadpour R, et al. Prognostic assessment in high-grade soft-tissue sarcoma patients: a comparison of semantic image analysis and radiomics. Cancers. 2021;13(8):1929.
   PubMed Web of Science ®Google Scholar
• Nardone V, Boldrini L, Grassi R, et al. Radiomics in the setting of neoadjuvant radiotherapy: a new approach for tailored treatment. Cancers. 2021;13(14):3590.
   PubMed Web of Science ®Google Scholar